Skip to main content
INMB logo

INMB · Inmune Bio, Inc. · Documents

Track INMB — free
$0.89 0.00 (-0.47%) Play latest call Q3 2026 earnings call transcript
Market Cap
$27.68M
Shares
30.96M
Volume · Nov 20 7246 Avg daily vol (3M) 342.92K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $50K up 257.1% 10-K filed Mar 30, 2026 Quarterly report FY2026 Q3 Net loss $4.72M 10-Q filed Nov 5, 2026 Latest results Financial results 8-K filed Oct 30, 2025 Earnings call Q3 2026 earnings call Held Nov 5, 2026
2026
Nov 5
Earnings call
Ebstracell UK application targets early February 2027

ImmuneBio targets an early February 2027 UK application for Ebstracell, with potential approval by the middle of the year, and says cash will fund operations through Q3 2027.

3 source passages
We remain on track to complete a U.K. marketing authorization application in early February 2027, with potential U.K. approval by the middle of the year. We thank you for joining the call for ImmuneBio's third quarter 2026 financial results. Also, during October, the company raised $4.5 million in gross proceeds from the sale of common stock and warrants to an investor, and based on our current operating plan, we believe our cash is sufficient to fund our operations through Q3 of 2027. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
CORDStrom targets 2027 filings as going concern persists

INmune Bio plans to file CORDStrom’s UK Marketing Authorization Application during February 2027 and an FDA Biologics License Application at mid-2027. It reported a $11.4 million nine-month net loss, $16.3 million cash, and substantial doubt about continuing as a going concern.

Net loss $4.72M Diluted EPS -$0.17
Read from the MD&A section
6 source passages
CORDStrom has recently completed a pivotal, blinded, randomized cross-over trial. We intend to file a Marketing Authorization Application (“MAA”) in the United Kingdom during February 2027, followed by a Biologics License Application (“BLA”) with the U.S. Food and Drug Administration (“FDA”) planned for mid-2027 and then the European Union application. INmune Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed to reprogram the innate immune system. We reported a net loss of $11.4 million for the nine months ended September 30, 2026. As of September 30, 2026 and December 31, 2025, we had cash and cash equivalents of $16.3 million and $24.8 million, respectively. Our recurring net losses and negative cash flows from operations raised substantial doubt regarding our ability to continue as a going concern within one year after the issuance of our unaudited condensed consolidated financial statements for the nine months ended September 30, 2026. Open the document at this passage
Oct 29
Current report 8-K Events of Oct 27
Direct offering raises $4.5 million with warrants

Inmune Bio agreed to sell 3,000,000 shares at $1.50 per share and issue unregistered warrants for up to 3,000,000 additional shares, generating expected aggregate gross proceeds of $4.5 million before fees and expenses.

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure Read from the first part of this long document
3 source passages
On October 27, 2026, INmune Bio Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single investor (the “Purchaser”), pursuant to which the Company agreed to issue and sell to the Purchaser, in a registered direct offering (the “Registered Direct Offering”), 3,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an offering price of $1.50 per share. In a concurrent private placement (the “Private Placement” and, together with the Registered Direct Offering, the “Offering”), the Company also agreed to issue to the Purchaser unregistered warrants (the “Common Warrants”) to purchase up to 3,000,000 shares of Common Stock (the “Common Warrant Shares”). The Company expects to receive aggregate gross proceeds of $4.5 million from the Offering, before deducting placement agent fees and offering expenses and excluding the proceeds, if any, from the exercise of the Common Warrants sold in the Private Placement. Open the document at this passage
Oct 21
Current report 8-K
Ebstrocel pre-MAA package submitted to UK MHRA; Uniphar agreement signed

INmune Bio submitted its final pre-Marketing Authorisation Application package to the UK MHRA for Ebstrocel on October 20, 2026. The company targets a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review. It also entered into a Master Services Agreement with Uniphar Durbin Ireland Limited and expects to submit a U.S. BLA in Q2 2027.

Regulation FD disclosure, Other events
5 source passages
Final pre-MAA package submitted to MHRA on October 20, 2026 Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks with potential UK approval in mid-2027, subject to MHRA review entered into a Master Services Agreement with Uniphar Durbin Ireland Limited U.S. BLA expected to be submitted in Q2, 2027 Open the document at this passage
Jul 31
Current report 8-K
Other events AI summary on its way
Jun 23
Current report 8-K
Other events AI summary on its way
Jun 2
Current report 8-K
Other events AI summary on its way
May 14
Current report 8-K
Other events AI summary on its way
Apr 23
Proxy statement DEF 14A Meeting Jun 16, 2026
Proxy statement AI summary on its way
Mar 30
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $50K ▲ 257.1% Net loss $45.93M Diluted EPS -$1.86
Feb 23
Current report 8-K
Other events AI summary on its way
Feb 19
Current report 8-K
Other events AI summary on its way
2025
Showing 1–50 of 313 documents
Key facts CIK 1711754 CUSIP 45782T105 13F (30d) 70 filings 58 filers Visit website Investor relations